Protein kinase C-mediated protection of motoneurons from excitotoxicity

Neuroscience Letters

Volumn 439, Issue 2, 2008, Pages 143-146

  Tomimatsu, Naoko ^a   Arakawa, Yoshihiro ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

Amyotrophic lateral sclerosis; Glutamate; Motoneuron; Neurotrophic factor; Protein kinase C; Survival

Indexed keywords

2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; BRAIN DERIVED NEUROTROPHIC FACTOR; GLUTAMIC ACID; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DRUG MECHANISM; EMBRYO; EXCITOTOXICITY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; UPREGULATION;

ANIMALS; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EMBRYO, MAMMALIAN; ENZYME INHIBITORS; EXCITATORY AMINO ACIDS; GLUTAMIC ACID; INDOLES; MALEIMIDES; MOTOR NEURONS; NEUROPROTECTIVE AGENTS; PROTEIN KINASE C; RATS; SPINAL CORD; TETRADECANOYLPHORBOL ACETATE;

EID: 44649161175     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2008.05.004     Document Type: Article

References (36)

1. Aoki M., Kato S., Nagai M., and Itoyama Y. Development of a rat model of amyotrophic lateral sclerosis expressing a human SOD1 transgene. Neuropathology 25 (2005) 365-370
2. Arakawa Y., Nishijima C., Shimizu N., and Urushidani T. Survival-promoting activity of nimodipine and nifedipine in rat motoneurons: implications of an intrinsic calcium toxicity in motoneurons. J. Neurochem. 83 (2002) 150-156
3. Arakawa Y., Sendtner M., and Thoenen H. Survival effect of ciliary neurotrophic factor (CNTF) on chick embryonic motoneurons in culture: comparison with other neurotrophic factors and cytokines. J. Neurosci. 10 (1990) 3507-3515
4. BDNF-Group. A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III). Neurology 52 (1999) 1427-1433
5. Bensimon G., Lacomblez L., and Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 330 (1994) 585-591
6. Borasio G.D., Robberecht W., Leigh P.N., Emile J., Guiloff R.J., Jerusalem F., Silani V., Vos P.E., Wokke J.H., and Dobbins T. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 51 (1998) 583-586
7. CNTF-Group. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group. Neurology 46 (1996) 1244-1249
8. Cordey M., and Pike C.J. Conventional protein kinase C isoforms mediate neuroprotection induced by phorbol ester and estrogen. J. Neurochem. 96 (2006) 204-217
9. Felipo V., Minana M.D., and Grisolia S. Inhibitors of protein kinase C prevent the toxicity of glutamate in primary neuronal cultures. Brain Res. 604 (1993) 192-196
10. Gordon P.H., Moore D.H., Miller R.G., Florence J.M., Verheijde J.L., Doorish C., Hilton J.F., Spitalny G.M., MacArthur R.B., Mitsumoto H., Neville H.E., Boylan K., Mozaffar T., Belsh J.M., Ravits J., Bedlack R.S., Graves M.C., McCluskey L.F., Barohn R.J., and Tandan R. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 6 (2007) 1045-1053
11. Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X., Chen W., Zhai P., Sufit R.L., and Siddique T. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264 (1994) 1772-1775
12. Han Y.S., Zheng W.H., Bastianetto S., Chabot J.G., and Quirion R. Neuroprotective effects of resveratrol against beta-amyloid-induced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C. Br. J. Pharmacol. 141 (2004) 997-1005
13. Hu J.H., Zhang H., Wagey R., Krieger C., and Pelech S.L. Protein kinase and protein phosphatase expression in amyotrophic lateral sclerosis spinal cord. J. Neurochem. 85 (2003) 432-442
14. Ito T., Deng X., Carr B., and May W.S. Bcl-2 phosphorylation required for anti-apoptosis function. J. Biol. Chem. 272 (1997) 11671-11673
15. Jung Y.S., Lee B.K., Park H.S., Shim J.K., Kim S.U., Lee S.H., Baik E.J., and Moon C.H. Activation of protein kinase C-delta attenuates kainate-induced cell death of cortical neurons. Neuroreport 16 (2005) 741-744
16. Krieger C., Hu J.H., and Pelech S. Aberrant protein kinases and phosphoproteins in amyotrophic lateral sclerosis. Trends Pharmacol. Sci. 24 (2003) 535-541
17. Kwak S., and Kawahara Y. Deficient RNA editing of GluR2 and neuronal death in amyotrophic lateral sclerosis. J. Mol. Med. 83 (2005) 110-120
18. Lacomblez L., Bensimon G., Leigh P.N., Guillet P., and Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis/Riluzole Study Group II. Lancet 347 (1996) 1425-1431
19. Lacomblez L., Bensimon G., Leigh P.N., Guillet P., Powe L., Durrleman S., Delumeau J.C., and Meininger V. A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-II. Neurology 47 (1996) S242-S250
20. Lai E.C., Felice K.J., Festoff B.W., Gawel M.J., Gelinas D.F., Kratz R., Murphy M.F., Natter H.M., Norris F.H., and Rudnicki S.A. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology 49 (1997) 1621-1630
21. Lallemend F., Hadjab S., Hans G., Moonen G., Lefebvre P.P., and Malgrange B. Activation of protein kinase CbetaI constitutes a new neurotrophic pathway for deafferented spiral ganglion neurons. J. Cell Sci. 118 (2005) 4511-4525
22. Lange D.J., Felice K.J., Festoff B.W., Gawel M.J., Gelinas D.F., Kratz R., Lai E.C., Murphy M.F., Natter H.M., Norris F.H., and Rudnicki S. Recombinant human insulin-like growth factor-I in ALS: description of a double-blind, placebo-controlled study. North American ALS/IGF-I Study Group. Neurology 47 (1996) S93-S94 discussion S94-S95
23. Lin C.L., Bristol L.A., Jin L., Dykes-Hoberg M., Crawford T., Clawson L., and Rothstein J.D. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 20 (1998) 589-602
24. Louvel E., Hugon J., and Doble A. Therapeutic advances in amyotrophic lateral sclerosis. Trends Pharmacol. Sci. 18 (1997) 196-203
25. Mellor H., and Parker P.J. The extended protein kinase C superfamily. Biochem. J. 332 Pt 2 (1998) 281-292
26. Miller R.G., Petajan J.H., Bryan W.W., Armon C., Barohn R.J., Goodpasture J.C., Hoagland R.J., Parry G.J., Ross M.A., and Stromatt S.C. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group. Ann. Neurol. 39 (1996) 256-260
27. Miller R.G., Shepherd R., Dao H., Khramstov A., Mendoza M., Graves J., and Smith S. Controlled trial of nimodipine in amyotrophic lateral sclerosis. Neuromuscul. Disord. 6 (1996) 101-104
28. Nagao M., Kato S., Oda M., and Hirai S. Decrease of protein kinase C in the spinal motor neurons of amyotrophic lateral sclerosis. Acta Neuropathol. (Berl.) 96 (1998) 52-56
29. Nishijima C., Kimoto K., and Arakawa Y. Survival activity of troglitazone in rat motoneurons. J. Neurochem. 76 (2001) 383-390
30. Ruvolo P.P., Deng X., Carr B.K., and May W.S. A functional role for mitochondrial protein kinase Calpha in Bcl2 phosphorylation and suppression of apoptosis. J. Biol. Chem. 273 (1998) 25436-25442
31. Shaw B.F., and Valentine J.S. How do ALS-associated mutations in superoxide dismutase 1 promote aggregation of the protein?. Trends Biochem. Sci. 32 (2007) 78-85
32. Shibata N. Transgenic mouse model for familial amyotrophic lateral sclerosis with superoxide dismutase-1 mutation. Neuropathology 21 (2001) 82-92
33. Tan Y., Ruan H., Demeter M.R., and Comb M.J. p90(RSK) blocks bad-mediated cell death via a protein kinase C-dependent pathway. J. Biol. Chem. 274 (1999) 34859-34867
34. Traynor B.J., Bruijn L., Conwit R., Beal F., O'Neill G., Fagan S.C., and Cudkowicz M.E. Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology 67 (2006) 20-27
35. Wagey R., Hu J., Pelech S.L., Raymond L.A., and Krieger C. Modulation of NMDA-mediated excitotoxicity by protein kinase C. J. Neurochem. 78 (2001) 715-726
36. Wong P.C., Rothstein J.D., and Price D.L. The genetic and molecular mechanisms of motor neuron disease. Curr. Opin. Neurobiol. 8 (1998) 791-799